262 related articles for article (PubMed ID: 7550351)
1. Genomic imprinting of p57KIP2, a cyclin-dependent kinase inhibitor, in mouse.
Hatada I; Mukai T
Nat Genet; 1995 Oct; 11(2):204-6. PubMed ID: 7550351
[TBL] [Abstract][Full Text] [Related]
2. An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome.
Hatada I; Ohashi H; Fukushima Y; Kaneko Y; Inoue M; Komoto Y; Okada A; Ohishi S; Nabetani A; Morisaki H; Nakayama M; Niikawa N; Mukai T
Nat Genet; 1996 Oct; 14(2):171-3. PubMed ID: 8841187
[TBL] [Abstract][Full Text] [Related]
3. p57K1P2 is expressed in Wilms' tumor with LOH of 11p15.5.
Overall ML; Spencer J; Bakker M; Dziadek M; Smith PJ
Genes Chromosomes Cancer; 1996 Sep; 17(1):56-9. PubMed ID: 8889507
[TBL] [Abstract][Full Text] [Related]
4. Human p57(KIP2) defines a new imprinted domain on chromosome 11p but is not a tumour suppressor gene in Wilms tumour.
Taniguchi T; Okamoto K; Reeve AE
Oncogene; 1997 Mar; 14(10):1201-6. PubMed ID: 9121769
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase inhibitor p57KIP2 in soft tissue sarcomas and Wilms'tumors.
Orlow I; Iavarone A; Crider-Miller SJ; Bonilla F; Latres E; Lee MH; Gerald WL; Massagué J; Weissman BE; Cordón-Cardó C
Cancer Res; 1996 Mar; 56(6):1219-21. PubMed ID: 8640801
[TBL] [Abstract][Full Text] [Related]
6. Genomic imprinting of human p57KIP2 and its reduced expression in Wilms' tumors.
Hatada I; Inazawa J; Abe T; Nakayama M; Kaneko Y; Jinno Y; Niikawa N; Ohashi H; Fukushima Y; Iida K; Yutani C; Takahashi S; Chiba Y; Ohishi S; Mukai T
Hum Mol Genet; 1996 Jun; 5(6):783-8. PubMed ID: 8776593
[TBL] [Abstract][Full Text] [Related]
7. Selective maternal-allele loss in human lung cancers of the maternally expressed p57KIP2 gene at 11p15.5.
Kondo M; Matsuoka S; Uchida K; Osada H; Nagatake M; Takagi K; Harper JW; Takahashi T; Elledge SJ; Takahashi T
Oncogene; 1996 Mar; 12(6):1365-8. PubMed ID: 8649840
[TBL] [Abstract][Full Text] [Related]
8. Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma.
Lai S; Goepfert H; Gillenwater AM; Luna MA; El-Naggar AK
Clin Cancer Res; 2000 Aug; 6(8):3172-6. PubMed ID: 10955800
[TBL] [Abstract][Full Text] [Related]
9. Overgrowth syndromes and genomic imprinting: from mouse to man.
Li M; Squire JA; Weksberg R
Clin Genet; 1998 Mar; 53(3):165-70. PubMed ID: 9630066
[TBL] [Abstract][Full Text] [Related]
10. Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour.
Ogawa O; Eccles MR; Szeto J; McNoe LA; Yun K; Maw MA; Smith PJ; Reeve AE
Nature; 1993 Apr; 362(6422):749-51. PubMed ID: 8097018
[TBL] [Abstract][Full Text] [Related]
11. Coding mutations in p57KIP2 are present in some cases of Beckwith-Wiedemann syndrome but are rare or absent in Wilms tumors.
O'Keefe D; Dao D; Zhao L; Sanderson R; Warburton D; Weiss L; Anyane-Yeboa K; Tycko B
Am J Hum Genet; 1997 Aug; 61(2):295-303. PubMed ID: 9311733
[TBL] [Abstract][Full Text] [Related]
12. Genomic imprinting of a human apoptosis gene homologue, TSSC3.
Lee MP; Feinberg AP
Cancer Res; 1998 Mar; 58(5):1052-6. PubMed ID: 9500470
[TBL] [Abstract][Full Text] [Related]
13. Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15.
Matsuoka S; Thompson JS; Edwards MC; Bartletta JM; Grundy P; Kalikin LM; Harper JW; Elledge SJ; Feinberg AP
Proc Natl Acad Sci U S A; 1996 Apr; 93(7):3026-30. PubMed ID: 8610162
[TBL] [Abstract][Full Text] [Related]
14. Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann syndrome.
Zhang P; Liégeois NJ; Wong C; Finegold M; Hou H; Thompson JC; Silverman A; Harper JW; DePinho RA; Elledge SJ
Nature; 1997 May; 387(6629):151-8. PubMed ID: 9144284
[TBL] [Abstract][Full Text] [Related]
15. Genomic organization of the human p57KIP2 gene and its analysis in the G401 Wilms' tumor assay.
Reid LH; Crider-Miller SJ; West A; Lee MH; Massagué J; Weissman BE
Cancer Res; 1996 Mar; 56(6):1214-8. PubMed ID: 8640800
[TBL] [Abstract][Full Text] [Related]
16. p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene.
Matsuoka S; Edwards MC; Bai C; Parker S; Zhang P; Baldini A; Harper JW; Elledge SJ
Genes Dev; 1995 Mar; 9(6):650-62. PubMed ID: 7729684
[TBL] [Abstract][Full Text] [Related]
17. Imprinting status of 11p15 genes in Beckwith-Wiedemann syndrome patients with CDKN1C mutations.
Li M; Squire J; Shuman C; Fei YL; Atkin J; Pauli R; Smith A; Nishikawa J; Chitayat D; Weksberg R
Genomics; 2001 Jun; 74(3):370-6. PubMed ID: 11414765
[TBL] [Abstract][Full Text] [Related]
18. p57KIP2 targeted disruption and Beckwith-Wiedemann syndrome: is the inhibitor just a contributor?
Swanger WJ; Roberts JM
Bioessays; 1997 Oct; 19(10):839-42. PubMed ID: 9363677
[TBL] [Abstract][Full Text] [Related]
19. Divergently transcribed overlapping genes expressed in liver and kidney and located in the 11p15.5 imprinted domain.
Cooper PR; Smilinich NJ; Day CD; Nowak NJ; Reid LH; Pearsall RS; Reece M; Prawitt D; Landers J; Housman DE; Winterpacht A; Zabel BU; Pelletier J; Weissman BE; Shows TB; Higgins MJ
Genomics; 1998 Apr; 49(1):38-51. PubMed ID: 9570947
[TBL] [Abstract][Full Text] [Related]
20. CDKN1C expression in Beckwith-Wiedemann syndrome patients with allele imbalance.
Algar EM; Deeble GJ; Smith PJ
J Med Genet; 1999 Jul; 36(7):524-31. PubMed ID: 10424812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
